Experimental cell therapy for Hard-to-Treat cancers hits early snag

NCT ID NCT05868915

Terminated Disease control Sponsor: Hervor Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The study was terminated after enrolling only 1 person, so we have very limited information on safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HV-101 (tumor-infiltrating lymphocyte cells) plus chemotherapy (fludarabine, cyclophosphamide) and IL-2
What this could lead to: If successful, this approach could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This was a very early, small trial (only 1 participant enrolled) that was terminated, so we have very little data. TIL therapy can cause serious side effects from the chemotherapy and immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Renmin Hospital of Wuhan University

Wuhan, Hubei, 430060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.